GlassScriptPhysician profile
Jamie B Walters
NPI 1093966897
$10,490.79
in general payments reported to CMS, 2019-2025
36 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,893 · 2020: $705 · 2021: $973 · 2022: $1,795 · 2023: $2,370 · 2024: $1,824 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,093 · Education: $31.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,093.06 |
| Education | $31.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,995.18 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $1,808.16 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,031.93 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $761.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $613.78 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $492.21 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $351.56 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $303.31 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $285.27 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $183.72 | 2019-2023 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $169.29 | 2019-2024 | Ocaliva |
| Allergan, INC. | $157.38 | 2019 | |
| Nestle Healthcare Nutrition INC. | $142.19 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $121.71 | 2019-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $107.38 | 2019-2023 | Clenpiq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $106.28 | 2023-2024 | Idacio |
| Genzyme Corporation | $102.76 | 2022-2024 | |
| Enterra Medical, INC. | $97.30 | 2023 | |
| Aimmune Therapeutics, INC. | $88.04 | 2024-2025 | Vowst |
| Celltrion USA INC. | $67.53 | 2024 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $62.52 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $56.79 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $54.74 | 2024-2025 | Resmetirom, Rezdiffra |
| Merck Sharp & Dohme LLC | $47.08 | 2019-2023 | Dificid |
| Lilly USA, LLC | $39.46 | 2023-2024 | Omvoh |
| Romark Laboratories, Lc | $35.82 | 2019 | |
| Amgen INC. | $34.21 | 2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $25.00 | 2021 | |
| Covidien LP | $24.27 | 2019 | |
| Gilead Sciences, INC. | $22.59 | 2025 | |
| Evoke Pharma, INC. | $21.15 | 2021 | |
| Vivus LLC | $18.87 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.47 | 2022 | |
| Ucb, INC. | $15.09 | 2019 | |
| Medtronic, INC. | $14.35 | 2021 | |
| Olympus America INC. | $14.32 | 2023 | Endoclot Phs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.